<code id='4AFA090BB6'></code><style id='4AFA090BB6'></style>
    • <acronym id='4AFA090BB6'></acronym>
      <center id='4AFA090BB6'><center id='4AFA090BB6'><tfoot id='4AFA090BB6'></tfoot></center><abbr id='4AFA090BB6'><dir id='4AFA090BB6'><tfoot id='4AFA090BB6'></tfoot><noframes id='4AFA090BB6'>

    • <optgroup id='4AFA090BB6'><strike id='4AFA090BB6'><sup id='4AFA090BB6'></sup></strike><code id='4AFA090BB6'></code></optgroup>
        1. <b id='4AFA090BB6'><label id='4AFA090BB6'><select id='4AFA090BB6'><dt id='4AFA090BB6'><span id='4AFA090BB6'></span></dt></select></label></b><u id='4AFA090BB6'></u>
          <i id='4AFA090BB6'><strike id='4AFA090BB6'><tt id='4AFA090BB6'><pre id='4AFA090BB6'></pre></tt></strike></i>

          Home / hotspot / focus

          focus


          focus

          author:entertainment    Page View:34
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In